Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemED(+)-GalactosaminehydrochlorideCat.No.:HY-42682CASNo.:1772-03-8Synonyms:D-Galactosaminehydrochloride分?式:C?H??ClNO?分?量:215.63作?靶點:Others作?通路:Others儲存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實驗H2O:100mg/mL(463.76mM;Needultrasonic)DMSO:50mg/mL(231.88mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM4.6376mL23.1879mL46.3757mL5mM0.9275mL4.6376mL9.2751mL10mM0.4638mL2.3188mL4.6376mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(11.59mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(11.59mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(11.59mM);Clearsolution4.請依序添加每種溶劑：PBSSolubility:100mg/mL(463.76mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性D(+)-Galactosamine(D-Galactosamine)hydrochloride?種已確定的實驗毒素，主通過產(chǎn)??由和UTP核苷酸的消耗引起肝損傷。D(+)-Galactosaminehydrochloride中毒也會導(dǎo)致腎功能不全，所以，腎功能衰竭通常和終末期肝損傷有關(guān)。脂多糖/D(+)-Galactosamine誘導(dǎo)的急性肝損傷?種已知的發(fā)性肝衰竭動物模型。REFERENCES[1].AyhanciA,etal.ProtectiveeffectsofellagicacidinD-galactosamine-inducedkidneydamageinrats.Cytotechnology.2016;68(5):1763-1770.[2].OkumuraA,etal.Alleviationoflipopolysaccharide/d-galactosamine-inducedliverinjuryinleukocytecell-derivedchemotaxin2deficientmice.BiochemBiophysRep.2017;12:166-171.Published2017Oct13.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel: